A public commission in Denmark has recommended the cessation of subsidies for GLP-1 drugs, including Ozempic and similar medications, as a primary treatment for type 2 diabetes.
Eli Lilly And Co (NYSE: LLY) released topline results from the LIBRETTO-531 study evaluating Retevmo versus the physician's choice of the multikinase inhibitors (MKIs) cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET)-mutan
Goldman Sachs Group is making notable shifts in its stance on two players in the investment banking sector. A Tuesday note issued to investors highlighted an upgrade for an asset management company and a downgrade for a financial restructuring business.